Case Report

Novel Biological Drug Helped Young Female with Severe Atopic Eczema Attend School after Two Years of Sick Leave

Author: Carl Swartling

Dupilumab is the first biological drug approved for the treatment of atopic eczema in adults. The drug inhibits Th2 mediated inflammation by blocking IL-4 and IL-13 pathways. We present a case-report involving a 17-year old female with severe atopic eczema who responded quickly on dupilumab injections. Prior to treatment she was on sick-leave for two years. One week after her first injection she could attend school. According to calculations made by Swedish medical authorities, approximately 1% of the Swedish population could potentially benefit from dupilumab.